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Abstract
Background:  Interstital cystitis is often treated with exogenous glycosaminoglycans such as
heparin, chondroitin sulphate (Uracyst), hyaluronate (Cystistat) or the semi-synthetic pentosan
polysulphate (Elmiron). The mechanism of action is presumed to be due to a coating of the bladder
surface to replace the normally present chondroitin sulphate and heparan sulphate lost as a result
of the disease. This study used fluorescent labelled chondroitin sulphate to track the distribution
of glycosaminoglycans administered intravesically to mouse bladder that had been damaged on the
surface.
Methods: The surfaces of mouse bladders were damaged by 3 mechanisms – trypsin, 10 mM HCl,
and protamine sulphate. Texas Red-labeled chondroitin sulphate was instilled into the bladders of
animals with damaged bladders and controls instilled only with saline. Bladders were harvested,
frozen, and sectioned for examination by fluorescence.
Results: The normal mouse bladder bound a very thin layer of the labelled chondroitin sulphate
on the luminal surface. Trypsin- and HCl-damaged bladders bound the labelled chondroitin sulphate
extensively on the surface with little penetration into the bladder muscle. Protamine produced less
overt damage, and much less labelling was seen, presumably due to loss of the label as it complexed
with the protamine intercalated into the bladder surface.
Conclusion: Glycosaminoglycan administered intravesically does bind to damaged bladder. Given
that the changes seen following bladder damage resemble those seen naturally in interstitial cystitis,
the mechanisms proposed for the action of these agents is consistent with a coating of damaged
bladder.
Background
Interstitial cystitis (IC) is being re-examined within a
broader context of chronic pelvic pain and pelvic floor
dysfunction with the result that it is being recognized that
the prevalence of IC is much higher than previously esti-
mated [1,2]. It has long been evident that, whatever the
cause, IC is a disease of the urothelium and the symptoms
are triggered by urine [3]. In general, the bladder exhibits
thinning and denudation of urothelium and distinctive
changes in the muscle [4], and there is very strong evi-
dence that the urothelium fails to differentiate properly in
IC [5,6]
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One of the main therapeutic approaches is so-called "gly-
cosaminoglycan (GAG) replacement therapy." This is
partly based upon earlier observation that the so-called
"GAG Layer" is lost or damaged in the interstitial cystitis
bladder [6,7]. The "GAG Layer" is a complex set of prote-
oglycans and glycoproteins on the bladder surface has
been isolated and characterized from cow and human
bladder [8-11]. Whether or not glycosaminoglycans actu-
ally restore impermeability of the bladder in interstitial
cystitis is controversial [12-15]. Nonetheless, many
patients respond to intravesical instillations of pentosan
polysulphate (Elmiron) [16], hyaluronate (Cystistat)
[17], chondroitin sulphate (Uracyst) [18]or heparin [19].
In this paper, we use three different models of bladder
damage to determine whether GAG instilled intravesically
actually binds preferentially to damaged bladder. We pre-
pared a fluorescent-labeled chondroitin sulphate mole-
cule by covalently attaching Texas Red to the reducing
terminus of the GAG chain and then observing bladder
sections by fluorescence to determine where the labelled
GAG was found.
Methods
Texas Red-labelled chondroitin sulphate was prepared by
mixing 10 µL Texas Red Hydrazide (Molecular Probes,
Eugene, OR), 10 mM in dimethyl formamide, 40 µL of 1
mM chondroitin sulphate (Stellar Healthcare, London,
Ontario), and 5 µL of 50% acetic acid, The chondroitin
sulphate was assumed to be 20,000 molecular weight,
yielding a concentration of 20 mg/ml as being equivalent
to 1 mM. The reaction was allowed to occur overnight at
room temperature. The next morning, the bond was
reduced and made permanent by adding 10 µL of 150 mM
sodium cyanoborohydride for 2 h. The labelled ChS was
separated from unincorporated label by gel filtration on
Biogel P-4.
Mice (C57BL/6NHsd, 9–10 weeks old) were anesthetized
by intraperitoneal injection of ketamine 40 mg/kg and
xylazine 5–10 mg/kg and catheterized with a 24 Ga × 3/4"
intravenous catheter (Terumo Medical, Elkton, MD).
Bladder damage was produced by 3 methods. (a) Pro-
tamine, 1 mg/ml, was instilled into the bladder until full-
ness and allowed to remain for 10 minutes. The
protamine was then washed out with 3 fillings of buffered
saline. (b) Dilute HCl, 10 mM was prepared by dilution in
saline and was administered in the same way as described
for the protamine except that a 0.1 M sodium bicarbonate
wash was used as the first rinse;. (c) Trypsin, 1 mg/ml, was
dissolved in saline and instilled into the mouse bladder
where it was allowed to remain for 30 min. The trypsin
was washed out with three fillings of buffered saline. Con-
trol animals were treated with buffered saline only. Three
animals were in each group. The mouse bladders were
then filled with Texas Red-labeled chondroitin sulphate,
which was allowed to remain for 1 hr. The bladder was
gently rinsed as described above. The animals were then
euthanized by cervical dislocation with death being con-
firmed by opening the chest. The bladders were removed,
flash frozen in OCT, and sections were obtained for
fluorescence.
The bladders were sectioned (2 µm thick) with a cryostat
and then examined first by ordinary fluorescence (2 sec-
tions per animal) and then by confocal microscopy using
a Leica TCS NT confocal system (1 section). A representa-
tive field was selected for confocal microscopy. Texas Red
emission was stimulated with excitation at 568 nm and
the fluorescence was collected using a 630 nm bandpass
filter. The nuclei were visualized by labelling with 20 µM
Hoechst 33259. Sections were also stained with hematox-
ylin and eosin (H&E) and a low-pH Alcian Blue counter-
stained with Nuclear Fast Red. For analysis of the
fluorescence intensities to assess relative binding, areas of
urothelium in the image were outlined with the "lasso"
tool of PhotoShop. Total pixels within the area were
counted. The red colour was then detected within that
area and the average brightness and number of pixels was
calculated. The integrated intensity was calculated as the
average pixel intensity × number of red pixels/total area in
pixels. For the controls, the unenhanced image was used
so that it would be comparable to the other images.
Images were interpreted without knowledge of the
treatment.
Results
Figure 1 shows that each of the models of bladder damage
produces a different pattern of damage. This figure shows
both a conventional H&E stain (A) and an Alcian Blue
stain (B) with the fluorescent images shown in (C). The
controls showed an even urothelium with a well-formed
endogenous "GAG layer" that appeared as a thin, blue line
on the luminal surface of the urothelium. The luminal
surface was even and showed the characteristic umbrella
cells. The separation of the entire urothelium from the
stroma seen in all the damaged bladders probably repre-
sents actual damage induced by, for example, edema
resulting from loss of permeability rather than an artefact
of sectioning. Trypsin removed most of the entire
umbrella cell layer along with the "GAG layer." Protamine
treatment produced little overt urothelial damage, but did
roughen the luminal surface. The dilute HCl treatment
also stripped off the umbrella cells and weakened the con-
nection between urothelium and the stroma.
As shown in the fluorescence images, in control animals
which experienced only saline instillation into the blad-
der, the label was found only on a narrow band corre-
sponding to the luminal cell layer. The amount of TR-BMC Urology 2005, 5:4 http://www.biomedcentral.com/1471-2490/5/4
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Damage produced by each model of bladder damage and binding of Texas Red-labelled chondroitin sulphate to mouse bladder Figure 1
Damage produced by each model of bladder damage and binding of Texas Red-labelled chondroitin sulphate 
to mouse bladder. Images in the first two columns are transmitted light images of bladder sections stained with H&E or Acid 
Alcian Blue to demonstrate bladder damage. Acid Alcian Blue binds to glycosaminoglycans and therefore stains the connective 
tissue and the "GAG Layer," which is indicated by arrows in the control image. The fluorescence images are digitally combined 
images of Hoechst 33258 fluorescence (blue) to show nuclei and Texas Red-labelled chondroitin sulphate (red). Arrows have 
been added to the fluorescence image of the protamine-treated bladder to show the location of the urothelium. From top to 
bottom, the rows show the controls, bladders treated with 1 mg/ml trypsin (30 min), 1 mg/ml protamine (10 min) and 10 mM 
HCl (10 min.) respectively. The fluorescence image of the control was digitally enhanced to demonstrate the small amount of 
binding that occurred, but which was undetectable at the settings used for the other images (Table 1).BMC Urology 2005, 5:4 http://www.biomedcentral.com/1471-2490/5/4
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labeled chondroitin sulphate that actually bound to the
controls was minimal, and the image shown in the figure
was digitally enhanced to visualize the small amount that
did bind. The dilute HCL damage model and the trypsin-
damage model showed increased binding of the label to
the bladder surface, but the binding still was confined
mainly to the damaged urothelium. In the protamine
damage model, the amount of binding was reduced. In no
case, however, was significant penetration of the bladder
by the label seen. Table 1 shows the quantitative image
densitometry measurement of the amount of red fluores-
cence found at the urothelial surface of each of the images.
Binding to the normal bladder surface was undetectable,
but could be revealed by digital enhancement of the
image. The trypsin- and HCl-damaged bladders bound
the most labelled chondroitin sulphate, whereas the pro-
tamine damaged bladder bound about 1/5th the amount
bound by the other two models. These values are consist-
ent with the level of damage observed.
Discussion
Although large placebo responses have clouded clinical
trials of replacement GAG therapy, thousands of patients
have benefited from therapy with one of the agents used
for allegedly replacing the bladder "GAG Layer." The
mechanism of action could arise from physically coating
the bladder surface and restoring impermeability as Par-
sons has claimed [19], or could be due to a more complex
mechanism [20]. The normal urothelium has minimal
affinity for chondroitin sulphate and binds it only on the
luminal surface of the umbrella cells in miniscule quanti-
ties. However, the chondroitin sulphate did not penetrate
into the deeper muscle layers of the bladder when the
urothelium was damaged or destroyed, but bound exten-
sively to the damaged bladder surface. Two of the bladder
models yielded virtually identical results, but the pattern
seen with protamine damage was different, and less chon-
droitin sulphate was bound than was observed in the
trypsin and dilute HCl damage models. Lewis and co-
workers [21] observed that protamine was inserted into
the apical cell membrane, destroying the permeability
barrier, but that glycosaminoglycans extracted the pro-
tamine, thereby restoring the bladder impermeability.
Our findings are not inconsistent with this model, in
which case both the extracted protamine and its com-
plexed chondroitin sulphate would be removed with the
fluid. The net result could be decreased binding of the
label. However, the protamine instillation produced less
overt damage as well.
The observed pattern of binding to damaged bladder sug-
gests that its main action is on the urothelial surface and
is not due to a pharmacologic effect. Both heparin and
pentosanpolysulphate have pharmacologic effects on the
coagulation system [22], whereas chondroitin sulphate, a
normal constituent of the bladder surface, and hyaluro-
nate do not [23]. All of these glycosaminoglycan mole-
cules have effects on mast cells and other cells within the
bladder at high concentrations in vitro [24-26]. The fact
that all of these glycosaminoglycan molecules alleviate
symptoms in some patients in spite of not penetrating
into the bladder and remaining on the surface, even in the
face of extensive damage, suggests a physical effect is
responsible for clinical efficacy at least of chondroitin
sulphate.
We suggest that one possible mechanism for the symp-
tom-relieving effect of this class of compounds is they
may exclude urinary proteases rather than salts. Theoreti-
cal calculations based on actual measurements of the
amount of glycosaminoglycan found normally on the
human bladder surface showed the presence of a dense
layer of glycosaminoglycan will yield a bound water layer
that reduces the concentration of salts at the bladder sur-
face [20]. Lewis and Clausen earlier had demonstrated
that urinary proteases degrade bladder ion channels [27],
and Negrete and co-workers demonstrated the impermea-
bility of rabbit bladder lay in the apical membrane [15].
Because the highly charged GAG layer with its attendant
bound water layer would be a far more significant barrier
for macromolecules than small, inorganic ions, we specu-
late that the GAG layer may normally function to exclude
macromolecules rather than salts. Therefore the therapeu-
tic benefit of exogenous glycosaminoglycans may result
Table 1: Comparison of binding of TR-labeled Chondroitin Sulphate to bladder urothelium in experimental bladder damage.
Control Trypsin Protamine Dil. HCl
Mean pixel intensity 0 139 ± 17 167 ± 24 156 ± 28
Red Area (pixels) 0 5,952 2,058 4,814
Urothelial Area (pixels) 366,025 81,879 79,623 64,528
Normalized Red 0 0.0727 0.0133 0.0746
Integrated Red 0 10.1 ± 1.3 2.2 ± 0.3 11.6 ± 2.1BMC Urology 2005, 5:4 http://www.biomedcentral.com/1471-2490/5/4
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from exclusion of proteases or other macromolecules
from the bladder surface where they could produce addi-
tional damage.
Conclusion
Chondroitin sulphate instilled intravesically into three
animal models of bladder damage coated the damaged
bladder surface and failed to penetrate the bladder. This
suggests they act at the bladder surface rather than in
deeper layers of the bladder.
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